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Experimental studies have demonstrated that admin-istration or endogenous mobilization of bone mar-
row–derived progenitor cells limit cardiac injury and 
dysfunction after prolonged myocardial ischemia.1,2 There 
is strong evidence, supporting the notion that vascular and 
proangiogenic effects of bone marrow–derived mononuclear 
or CD34+ progenitor cells play an important role in their 
capacity to ameliorate cardiac dysfunction after myocardial 
infarction (MI), based on a specific suicide gene approach 
or by blocking VEGF (vascular endothelial growth factor) 
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Objective—Proangiogenic effects of mobilized bone marrow–derived stem/progenitor cells are essential for cardiac repair 
after myocardial infarction. MicroRNAs (miRNA/miR) are key regulators of angiogenesis. We investigated the differential 
regulation of angio-miRs, that is, miRNAs regulating neovascularization, in mobilized CD34+ progenitor cells obtained 
from patients with an acute ST-segment–elevation myocardial infarction (STEMI) as compared with those with stable 
coronary artery disease or healthy subjects.
Approach and Results—CD34+ progenitor cells were isolated from patients with STEMI (on day 0 and day 5), stable 
coronary artery disease, and healthy subjects (n=27). CD34+ progenitor cells of patients with STEMI exhibited increased 
proangiogenic activity as compared with CD34+ cells from the other groups. Using a polymerase chain reaction–based 
miRNA-array and real-time polymerase chain reaction validation, we identified a profound upregulation of 2 known 
angio-miRs, that are, miR-378 and let-7b, in CD34+ cells of patients with STEMI. Especially, we demonstrate that 
miR-378 is a critical regulator of the proangiogenic capacity of CD34+ progenitor cells and its stimulatory effects on 
endothelial cells in vitro and in vivo, whereas let-7b upregulation in CD34+ cells failed to proof its effect on endothelial 
cells in vivo.
Conclusions—The present study demonstrates a significant upregulation of the angio-miRs miR-378 and let-7b in mobilized 
CD34+ progenitor cells of patients with STEMI. The increased proangiogenic activity of these cells in patients with 
STEMI and the observation that in particular miR-378 regulates the angiogenic capacity of CD34+ progenitor cells in vivo 
suggest that this unique miRNA expression pattern represents a novel endogenous repair mechanism activated in acute 
myocardial infarction.  (Arterioscler Thromb Vasc Biol. 2017;37:341-349. DOI: 10.1161/ATVBAHA.116.308695.)
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by specific antibodies.3,4 Moreover, the administration of ex 
vivo expanded early outgrowth cells or CD34+ progenitor 
cells increases myocardial neovascularization in the border 
zone of the infarction and improves left ventricular ejection 
function after MI.5,6 Fazel et al7 have observed that mobi-
lization of bone marrow–derived progenitor cells after MI 
was impaired in mice with a mutation of the c-kit receptor, 
and this was associated with a reduced cardiac neovascu-
larization and more pronounced left ventricular dysfunc-
tion. These studies support the notion that endogenous 
bone marrow–derived progenitor cells are critical for the 
angiogenic switch in the infarct border zone, that is, the 
stimulation of cardiac neovascularization and preservation 
of cardiac function after MI. The proangiogenic capacity of 
progenitor cells in patients after acute coronary syndrome 
(ACS) is therefore likely important for their capacity to 
promote cardiac repair mechanisms. However, the exact 
molecular mechanisms contributing to the functional acti-
vation of progenitor cells mobilized in the context of an 
ACS remain to be defined.
Notably, microRNAs (miRNAs), small (≈22-nucleotide) 
noncoding RNAs have been identified as novel regulators of 
angiogenic processes, progenitor cell differentiation, and in 
particular cardiovascular cell fate decisions.8–11 The crucial 
role of miRNAs in the cardiovascular system is further sup-
ported by the finding that depletion of the miRNA-process-
ing enzyme Dicer leads to embryonic lethality because of 
defects in vessel formation and cardiac development.12
The present study was therefore designed to character-
ize the proangiogenic effects and differential expression of 
miRNAs regulating angiogenesis in CD34+ progenitor cells of 
patients with an acute ST-segment–elevation MI (STEMI) as 
compared with healthy subjects and patients with stable coro-
nary artery disease (sCAD).
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Study Population
CD34+ progenitor cells were isolated prospectively from 
patients with acute and 5-day-old STEMI, patients with sCAD, 
and healthy subjects enrolled in the Swiss SPUM-ACS regis-
try (www.spum-acs.ch). All 3 study groups were age and sex 
matched. The baseline characteristics of the study population 
are shown in the Table. Detailed information about the inclu-
sion and exclusion criteria is described in the Materials and 
Methods in the online-only Data Supplement. The isolated 
CD34+ cells were CD45+ positive. A small number of circu-
lating CD34+ cells, ≈1.5% were positive for CXCR4-receptor. 
Fluorescence-activated cell sorter results for CD34+ after the 
isolation are presented in Figure I in the online-only Data 
Supplement.
Proangiogenic Capacity of CD34+ Progenitor 
Cells From Patients With Acute STEMI 
Is Increased as Compared With Patients 
With sCAD and Healthy Subjects
The proangiogenic capacity of circulating CD34+ progeni-
tor cells obtained from patients with STEMI at different time 
points after the event was examined and compared with cir-
culating CD34+ progenitor cells of patients with sCAD and 
healthy subjects. We observed a significant increase in the 
proangiogenic capacity of CD34+ progenitor cells in patients 
with an acute STEMI as compared with patients with sCAD 
or healthy subjects (Figure 1A).
Differential miR-Expression in CD34+ 
Progenitor Cells From Patients With STEMI as 
Compared With sCAD and Healthy Subjects
MiRNAs have been identified as critical regulators of angio-
genic pathways.8–11 Thus, we performed a polymerase chain 
reaction–based miRNA array (including 372 miRs) to detect 
differentially regulated miRNAs in mobilized CD34+ progeni-
tor cells of patients with STEMI as compared with those with 
sCAD or healthy subjects (Table I in the online-only Data 
Supplement). Thirty-six miRNAs were significantly deregu-
lated in CD34+ progenitor cells of patients with STEMI as 
compared with healthy subjects (Figure II in the online-only 
Data Supplement). To investigate the proangiogenic func-
tion of CD34+ progenitor cells, we selected 2 known angio-
miRs, let-7b and miR-378,11,13,14 which were consistently 
upregulated in both, the real-time polymerase chain reaction 
screening array and the validation studies (Figure 2A and 2B), 
suggesting a potential role of these miRNAs in the regulation 
of proangiogenic effects of CD34+ progenitor cells. Other 
miRNAs of the validation studies, which were confirmed to 
be substantially upregulated in mobilized CD34+ progenitor 
cells after MI, were members from the miR-181-family, that 
is, miR-181a, miR-181b, and miR-181d (Figure 2C through 
2E). Notably, miR-378, miR-181a, miR-181b, and miR-181d 
were significantly deregulated when compared with not only 
healthy subjects but also patients with sCAD (Figure 2A, 2C 
through 2E). No significant differences between the groups 
could be confirmed in the validation study for the other miR-
NAs (Figure III in the online-only Data Supplement).
Increased Proliferation of Pre–miR-378– 
and Pre–let-7b–Transfected CD34+ 
Cells in WST1 Proliferation Assay
It is known that the number of circulating CD34+ progenitor 
cells is increased in peripheral blood after MI.15 Therefore, 
we performed in vitro proliferation experiments with WST1 
Nonstandard Abbreviations and Acronyms
ACS acute coronary syndrome
miRNA/miR microRNA
MI myocardial infarction
PECAM-1 platelet endothelial cell adhesion molecule
sCAD stable coronary artery disease
STEMI ST-segment–elevation myocardial infarction
SuFu suppressor of fused
VEGF vascular endothelial growth factor
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reagent, which revealed significantly increased proliferation 
after 24 hours for transfected CD34+ cells with pre–miR-378 
and pre–let-7b, compared with control transfected cells 
(Figure 3A; Figure IVA in the online-only Data Supplement). 
In contrast, anti-miR-transfection of miR-378 and let-7b 
(Figure 3B; Figure IVB in the online-only Data Supplement), 
as pre– and anti–miR-181a (Figure IVC and IVD in the 
online-only Data Supplement), showed no significant effect 
on CD34+ cell proliferation.
Increased Proangiogenic Capacity of 
miR-let-7b and miR-378 but not of miR-
181a–Transfected CD34+ Cells in In Vitro 
Angiogenic Assays and Migration Assays
To determine whether miR-let-7b and miR-378 are regulat-
ing the angiogenic capacity of CD34+ progenitor cells, CD34+ 
cells obtained from healthy subjects were first transfected 
with the pre-miR or scramble-miR, respectively. The trans-
fection efficiency is shown in Figure V in the online-only 
Table.  Characteristics of Study Population (n=27)
Study Groups Healthy Subjects sCAD STEMI (Day 0) P Value
Characteristics mean±SD
  Male, n (%) 7 (77.8) 7 (77.8) 7 (77.8) 1.000
  Women, n (%) 2 (22.2) 2 (22.2) 2 (22.2) 1.000
  Age, y 53.9±5.9 61.9±6.6 57.3±7.6 0.061
  BP syst., mm Hg 120.0±9.3 142.1±15.6 134.6±25.7 0.048
  BP diast., mm Hg 73.7±9.1 83.7±8.6 80.6±19.0 0.275
  HR, bpm 62.9±8.0 76.6±10.7 79.8±15.1 0.012
  CCS 0.0±0.0 2.0±0.9 4.0±0.0 <0.001
  LVEF, % 60.9±4.0 54.3±15.4 54.3±17.3 0.510
  BMI, kg/m2 24.5±2.9 26.4±3.6 30.2±3.8 0.016
Laboratory values mean±SD
  Trop T, μg/L <0.01 <0.01 2.2±2.6 <0.001
  CK max, STEMI only   834.2±788.1  
  CK-MB, U/L 11.4±3.9 15.1±7.9 74.9±77.9 0.014
  NT-pro-BNP, ng/L 52.4±52.7 148.1±129.7 694.2±943.3 0.002
  Creatinine, μmol/L 83.2±13.2 72.1±10.5 78.8±14.3 0.200
  Hb, g/dL 14.0±0.9 13.9±1.5 13.3±2.1 0.603
  WBC, 103/μL 5.5±0.9 7.1±2.1 10.1±3.4 0.001
  Thrombocytes, 103/μL 286.8±45.6 268.2±100.4 248.6±73.7 0.578
  Total cholesterol, mmol/L 5.6±0.9 4.9±1.4 4.5±1.5 0.202
  LDL cholesterol, mmol/L 3.4±1.0 3.0±1.1 2.8±1.4 0.623
  HDL cholesterol, mmol/L 1.7±0.5 1.3±0.3 1.1±0.3 0.006
  Triglycerides, mmol/L 1.1±0.5 1.4±0.7 1.2±0.6 0.680
Medication, n (%)
  Statins 0.0 (0.0) 7.0 (77.8) 5.0 (55.6) 0.003
  β-blockers 0.0 (0.0) 6.0 (66.7) 3.0 (33.3) 0.011
  Diuretics 0.0 (0.0) 1.0 (11.1) 0.0 (0.0) 0.354
  ACE-inhibitor 0.0 (0.0) 3.0 (33.3) 3.0 (33.3) 0.145
  AT-I-antagonist 0.0 (0.0) 1.0 (11.1) 1.0 (11.1) 0.583
  Calcium-channel blockers 0.0 (0.0) 1.0 (11.1) 0.0 (0.0) 0.354
  Aspirin 0.0 (0.0) 8.0 (88.9) 4.0 (44.4) <0.001
  Clopidogrel 0.0 (0.0) 3.0 (33.3) 2.0 (22.2) 0.179
ACE indicates angiotensin-converting enzyme; AT-I, angiotensin II receptor type I; BMI, body mass index; BP, 
blood pressure; CCS, Canadian Cardiovascular Society; CK, creatine kinase; CK-MB, creatine kinase MB-isoenzyme; 
Hb, hemoglobin; HDL, high-density lipoprotein; HR, heart rate; LDL, low-density lipoprotein; NT-pro-BNP, N-terminal 
prohormone brain natriuretic peptide; sCAD, stable coronary artery disease; STEMI, ST-segment–elevation myocardial 
infarction; Trop T, troponinT; and WBC, white blood count.
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Data Supplement. In vitro tube formation was significantly 
enhanced by coculture of human umbilical vein endothe-
lial cells (HUVECs) with pre–miR-378–transfected and 
pre–miR-let-7b–transfected CD34+ cells as compared with 
scramble-transfected CD34+ cells. Moreover, downregula-
tion of miR-378 and miR-let-7b in CD34+ cells using anti-
miRs resulted in a reduced capacity of CD34+ progenitor 
cells to promote tube formation in comparison to scramble-
miR–transfected CD34+ cells (Figure 4A; Figure VIA in the 
online-only Data Supplement). Despite, only HUVECs and 
not CD34+ progenitor cells form tube-like structures (Figure 
VII in the online-only Data Supplement).
In addition, using the endothelial scratch migration assay, 
we observed that CD34+ cells transfected with pre–miR-378 
or pre–miR-let-7b had an increased capacity to stimulate 
endothelial migration as measured by the endothelial migra-
tion index i (Figure 4B; Figure VIB in the online-only Data 
Supplement).
To date, the effects of miR-181a on angiogenesis have not 
been reported yet. Therefore, we performed angiogenesis tube 
formation assays in HUVECs transfected with pre–miR-181a 
and anti–miR-181a to determine its impact on angiogenesis and 
endothelial cells. Pre–miR-181a–transfected HUVECs showed 
a significantly decreased tube formation capacity, whereas 
anti–miR-181a transfection led to an increased tube formation 
activity (Figure VIII in the online-only Data Supplement).
In summary, the present findings are compatible with the 
notion that both miRNAs—let-7b and miR-378—regulate 
and augment the proangiogenic capacity of CD34+ cells and 
their stimulatory effects on vascular endothelial cells in vitro. 
Because of the marked antiangiogenic effects of miR-181a 
in endothelial cells, we did not perform further angiogenic 
experiments for this miRNA in CD34+ cells.
Paracrine Proangiogenic Impact of CD34+ Cells
For a long time, the proangiogenic capacity of CD34+ cells 
was associated with paracrine cytokine release.16 In our study, 
we performed an ELISA-based angiogenic cytokine Bioplex-
assay with supernatant, collected from transfected CD34+ 
cells. For PECAM-1 (platelet endothelial cell adhesion mol-
ecule), VEGF, leptin, and follistatin, we observed a nonsignifi-
cant increase after CD34+ cell transfection with pre–miR-378 
or pre–let-7b (Figure IXa and IXb in the online-only Data 
Supplement).
Microparticle-mediated transfer of miRNAs between dif-
ferent cell types is a possible mechanism for the paracrine 
effects.17 Thus, we performed a coculture assay containing 
transfected CD34+ cells and HUVECs, measuring the concen-
tration of selected miRNAs in the supernatant and HUVECs. 
Our results proofed equal miRNA-secretion of pre-miR–
transfected CD34+ cells (Figure 5A through 5C), whereas 
significant miRNA uptake in HUVECs could only be demon-
strated for miR-378 and miR-181a, but not for let-7b (Figure 
5D and 5E).
Augmented Angiogenic Capacity of Pre–miR-
378–Transfected Cells in In Vivo Angiogenic 
Experiments: Matrigel Plug Assay and 
Chorioallantoic Membrane Assay
We focused in our in vivo experiments on the proangiogenic 
function of miR-378. To characterize the role of miR-378 in 
CD34+ cells in vivo, we performed Matrigel plug assay with 
pre– and anti–miR-378–transfected CD34+ cells. Strikingly, 
pre–miR-378–transfected CD34+ cells significantly increased 
the amount of blood vessel sprouting in the matrigel plug, 
compared with scramble, whereas anti–miR-378 transfec-
tion resulted in significantly decreased blood vessel sprouting 
(Figure 6A). Notably, let-7b–transfected CD34+ cells did not 
impact in vivo blood vessel sprouting (Figure X in the online-
only Data Supplement).
Moreover, similar results for pre–miR-378–transfected 
CD34+ progenitor cells could be verified by chicken embryo 
in vivo angiogenesis assay. Increased in vivo blood ves-
sel sprouting was observed after incubation of chorioallan-
toic membrane with pre–miR-378–transfected CD34+ cells 
as compared with scrambled-miR–transfected CD34+ cells 
(Figure 6B).
Discussion
We here report that in mobilized CD34+ cells obtained from 
patients with STEMI miRNAs are differentially regulated. 
In our polymerase chain reaction–based miRNA-profiling 
analysis and subsequent validation studies with real-time 
polymerase chain reaction, we observed a significant upregu-
lation of 2 known angio-miRs, miR-378, and let-7b, in CD34+ 
progenitor cells obtained from patients with STEMI at the 
time of presentation, compared with healthy subjects and in 
Figure 1. Proangiogenic effects of CD34+ cells from patients 
with ST-segment–elevation myocardial infarction (STEMI), stable 
coronary artery disease (sCAD), and healthy subjects. Human 
umbilical vein endothelial cell (1×104) were cocultured for 18 h 
in matrigel with starvation medium EBM-2 (endothelial basal 
medium type 2) containing 0.5% fetal calf serum and with CD34+ 
cells (5×103) from healthy subjects, patients with sCAD, with 
STEMI d0, with STEMI d5 or in starvation medium containing 
50 ng/mL VEGF (vascular endothelial growth factor; as positive 
control) or without CD34+ cells (as negative control). Tube-like 
structures were quantified. *P<0.05, **P<0.01, ***P<0.001; data 
are mean±SEM.
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addition only for miR-378 compared with sCAD. Especially, 
we identified miR-378 as critical regulator of the proangio-
genic capacity of CD34+ progenitor cells and its stimulatory 
effects on endothelial cells in vitro and in vivo, whereas let-7b 
upregulation in CD34+ cells failed to exhibit relevant effects 
on endothelial cells in vivo.
The CD34+CD45+ progenitor cells population is also 
defined as early endothelial progenitor cells or as angiogenic 
cells. Early endothelial progenitor cells enhance neovascular-
ization indirectly via paracrine effects.18
Bone marrow–derived CD34+ progenitor cells are mobi-
lized in patients with an acute MI or in response to myo-
cardial ischemia.15,19,20 In this context, the investigated 
angio–miR-378 proofed to markedly increase CD34+ cell pro-
liferation, as measured by the WST1 reaction. Mobilization 
of CD34+ progenitor cells from the bone marrow into periph-
eral blood is associated with acute and chronic preservation 
of left ventricular function in patients with MI.19,21 Therefore, 
increased CD34+ cell count in response to miR-378–mediated 
proliferation supports the angiogenic effect of CD34+ cells in 
the context of an acute MI.
Indeed, several in vitro and in vivo studies have reported a 
proangiogenic effect of CD34+ cells.4,6 In particular, the effects 
of administration of bone marrow–derived mononuclear cells 
or CD34+ progenitor cells on recovery of left ventricular 
function after experimental MI have recently been related to 
their proangiogenic effects.3
Consistently, miRNAs, particularly angio-miRs, have been 
shown to regulate the proliferation, migration, and angiogenic 
capacity of endothelial cells.11,22 Xing et al23 demonstrated an 
increased proliferation and in vitro angiogenesis in mesen-
chymal cells under hypoxic conditions after miR-378 mimic 
Figure 2. Results of the miRNA profiling 
and validation with real-time polymerase 
chain reaction in CD34+ progenitor cells. 
MicroRNA expression levels for the  
miRNAs: A, miR-378, (B) let-7b,  
(C) miR-181a, (D) miR-181b, (E), miR-
181d in CD34+ progenitor cells isolated 
from healthy subjects, patients with  
stable coronary artery disease (sCAD), 
with ST-segment–elevation myocardial 
infarction (STEMI) d0, with STEMI d5. 
*P<0.05, **P<0.01, data are mean±SEM.
Figure 3. Proliferation assay. Proliferation of CD34+ progenitor 
cells (1×104) transfected with (A) pre–miR-378 and (B) anti–
miR-378, quantified with WST1 proliferation reagent. *P<0.05, 
data are mean±SEM.
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transfection. The present study further demonstrates a marked 
proangiogenic activation of CD34+ cells in patients with an 
acute STEMI and identifies the angio-miRs miR-378 and let-
7b, which are profoundly upregulated in these cells. To further 
investigate the functional role of these miRs with regards to 
proangiogenic capacity, CD34+ cells obtained from healthy 
subjects were transfected with pre–miR-378 and pre–miR-let-
7b or scrambled miRs. Elevated expression of miR-378 and 
let-7b increased the proangiogenic capacity of CD34+ cells 
in vitro by inducing tube formation. Moreover, transfection 
of CD34+ progenitor cells with both miRNAs (but not with 
scrambled miR) increased their stimulatory effect on endo-
thelial cells, that is, endothelial cell migration. Vice versa, 
downregulation of these angio-miRs using anti-miRs reduced 
the proangiogenic effects and migration effects of CD34+ pro-
genitor cells.
The regulation of angio-miR expression in CD34+ cells 
and the mechanism of interaction between endothelial cells 
and stem/progenitor cells are not fully understood. Recent evi-
dence suggests that CD34+ cells facilitate angiogenesis largely 
via paracrine effects.16
Hence, we performed the ELISA-based Bioplex 
Angiogenic Cytokine assay in supernatant of transfected 
CD34+ cells to investigate, whether the proangiogenic effects 
of angio-miRs in CD34+ cells are based on their paracrine 
secretion of proangiogenic cytokines. Our results revealed no 
significant changes, only a trend for increased release of fol-
listatin, PECAM-1, leptin, and VEGF in response to miR-378 
or let-7b overexpression.
Extracellular miRNAs were identified as a new signal-
ing pathway, which could be selectively exported for cell-
to-cell communication.24 These extracellular miRs must be 
protected against degradation by exonucleases. Therefore, 
they are included into microparticles such as exosomes, 
microvesicles, or apoptotic bodies or they are attached to pro-
tein complexes like argonaute 2 or lipoprotein-complexes.17 
Sahoo et al25 have reported that exosomes, secreted by CD34+ 
cells, improve angiogenesis in vivo and in vitro and that sev-
eral angio-miRs are enriched in their exosomes. Accordingly, 
we performed coculturing experiments of transfected CD34+ 
cells and HUVECs, which revealed that CD34+ cell-released 
angio-miR-378, but not let-7b, is taken up by HUVECs. Thus, 
transport of angio-miR-378 by microparticles released from 
CD34+ cells represents a novel, paracrine mechanism, contrib-
uting to their angiogenic effects on endothelial cells by direct 
endocytosis of the miR-378. These angio-miR–containing 
microparticles therefore likely represent an important mode 
of intercellular communication and exchange.
MiR-378 is enriched in CD34+ hematopoietic progenitor 
cells26 and has been suggested to promote angiogenesis by 
Figure 4. In vitro assays with scramble-
transfected CD34+ cells compared with 
pre–miR-378/anti–miR-378–transfected 
CD34+ cells. A, Tube formation angio-
genesis assay with human umbilical 
vein endothelial cells (HUVECs; 1×104) 
cocultered for 18 h with CD34+-trans-
fected cells (5×103). Tube-like structures 
were quantified. B, Endothelial scratch 
migration assay. After scratching, 
HUVECs were cultured in starvation 
medium with scramble/pre–miR-378–/
anti–miR-378–transfected CD34+ cells 
(4×104). The stimulatory effect of trans-
fected CD34+ cells on endothelial cell 
migration capacity was measured using 
the migration index (8 h after scratch). 
*P<0.05, **P<0.01, data are mean±SEM.
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targeting Suppressor of fused (SuFu) and Fus-1 expression 
and regulates cell survival.14 Moreover, nude mice injected 
with miR-378–transfected cancer cells formed substantially 
larger blood vessels as compared with GFP (green fluorescent 
protein)-transfected cells.14 Furthermore, miR-378 has been 
reported to promote VEGF expression by competing with 
miR-125a for the same seed region in the VEGF 3′-untrans-
lated region.14 Sufu and Fus-1 serve as targets for miR-378 
repression. Sufu functions as a negative regulator of Sonic 
hedgehog (Shh) signaling pathway. Shh promotes vessel 
formation by inducing expression of angiogenic cytokines, 
including VEGF and angiopoietin-1 (Ang-1) and -2 (Ang-2).27 
Therefore, miRNA-378 may promote angiogenesis by target-
ing Sufu and Fus-1, and hence indirectly upregulates angio-
genic factors.
Based on the results of the paracrine mechanism-demon-
strating experiments, we decided to focus our in vivo stud-
ies on miR-378–transfected CD34+ cells, offering the highest 
impact on paracrine angiogenic cytokine release and on angio-
miR-endothelial cell uptake.
Taken together, we transferred our recent findings 
from in vitro–based assays to in vivo angiogenesis mod-
els, such as in vivo matrigel plug assay and chorioallantoic 
membrane assay. Therefore, miR-378–transfected CD34+ 
cells significantly increased blood vessel infiltration and 
blood vessel sprouting, in support of our hypothesis. A 
limitation of the current miR-mimic experiments is the fact 
that substantially increased miR-378 levels may overesti-
mate the effects of more moderate changes of this miR in 
patients with MI.
Urbich et al28 indicated that CD34+ or CD 133+ EPCs from 
patients with sCAD show reduced endothelial regenerative 
function and impaired neovascularization. In line with this, 
our findings suggest an impaired angiogenic capacity for 
CD34+ cells in patients with sCAD. In this regard, mobilized 
and isolated CD34+ cells could be transfected by pre–miR-378 
to stimulate its proangiogenic capacity. Using this mecha-
nisms, the augmented proangiogenic capacity of CD34+ cells 
after STEMI could be transferred to CD34+ cells in patients 
with sCAD.
Moreover, our findings further indicate that the miR181-
family is strongly upregulated in CD34+ progenitor cells of 
patients with acute STEMI. More recently, it has been sug-
gested that increasing miR-181a levels stimulates depro-
gramming of lymphatic endothelial cells toward a blood 
vascular phenotype by targeting Prox1.29 After MI, the 
Figure 5. Coculture assays. MiRNA 
expression of (A and D) miR-378, (B and 
E) let-7b, and (C and F) miR-181a in 
supernatant and in human umbilical vein 
endothelial cell (HUVECs) after coculture 
with pre–miR-378–/miR-let-7b–/miR-
181–transfected CD34+ cells separated 
by 4-µm transwell inserts. *P<0.05, data 
are mean±SEM.
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miR-181 family is enriched in CD34+ cells and our coculture 
experiments demonstrated uptake of secreted miR-181a in 
endothelial cells. The role of upregulation of the miR-181 
family members for the differentiation of endothelial cells 
and blood vessel formation needs to be further elucidated in 
future studies.
In conclusion, we have identified miR-378 and partly let-
7b as differentially regulated miRNAs in circulating CD34+ 
progenitor cells from patients with STEMI, which critically 
modulate the proangiogenic and paracrine capacity of these 
cells. Furthermore, we investigated a link between miR-181 
family and MI. These findings reveal a novel mechanism con-
tributing to the proangiogenic activation of CD34+ progenitor 
cells in patients with an acute STEMI. Moreover, a novel use 
of pre–miR-378–transfected CD34+ cells in stem cell therapy 
for patients with sCAD seems possible.
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Figure 6. In-vivo assays. A, In vivo matri-
gel plug assay. Blood vessel infiltration in 
Matrigel plugs containing (1×105) scramble/
pre–miR-378–/anti–miR-378–transfected 
CD34+ cells was quantified by analysis of 
CD31-staining 5 d after injection. B, Chorioal-
lantoic membrane (CAM) angiogenesis assay in 
vivo. Difference of the vessel length 48 h after 
incubation with EGM-2 (endothelial growth 
medium type 2) medium, scramble-transfected 
CD34+ cells (scr. CD34+ cells) or with pre–miR-
378–transfected CD34+ cells (pre–miR-378 
CD34+ cells). *P<0.05, data are mean±SEM.
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Highlights
• Currently, CD34+ progenitor cells are used to increase revascularization after myocardial infarction.
• We investigated miRNAs involved in this process in isolated cells from patients with myocardial infarction and determined the proangiogenic 
miRNA-378, which proofed to be essential for the already known proangiogenic role of CD34+ progenitor cells.
• We successfully validated the proangiogenic impact of this miRNA on CD34+ progenitor cells derived from healthy subjects in vitro and in vivo.
• Our findings may lead to new therapeutic options in patients after myocardial infarction.
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Material and Methods 
 
Study population 
CD34+ progenitor cells were isolated prospectively from patients with acute STEMI 
diagnosed according to the ESC/AHA redefined guidelines(1), patients with stable CAD and 
healthy subjects. Patients with STEMI had a duration of chest pain of below 24 hours from 
the onset of symptoms till the presentation in the catheterization laboratory. CD34+ progenitor 
cells were isolated at baseline (day 0) and at day 5. Patients with stable CAD had 
angiographically documented stenosis above 50 % in at least one coronary vessel. Patients 
were excluded from the present study when one of the following criteria were present: Known 
history of leucopenia, thrombocytopenia, severe hepatic or renal dysfunction, heart failure, 
evidence of inflammatory or malignant disease as well as myocardial infarction within the last 
6 months in the sCAD group. Healthy subjects had no known cardiovascular disease, normal 
cardiac function validated by echocardiography, no structural heart disease, did not take any 
medication nor were smokers. The study protocol was carried out according to the principles 
of the Declaration of Helsinki and was approved by the local ethic committee. Written 
informed consent was obtained from all patients and healthy subjects before enrollment. 
 
Isolation of CD34+ progenitor cells and in-vitro culture 
CD34+ cells were isolated from 60 ml of anticoagulated peripheral blood (BD Vacutainer, 
K2EDTA 18.0 mg) or from Buffy Coats using the CD34-MicroBead-Kit (Miltenyi Biotec) 
according to the manufacturer’s protocol. In brief, peripheral blood mononuclear cells 
(PBMC) were isolated by density gradient centrifugation for 30min at 400g with LSM 1077 
(PAA Laboratories) and labeled with anti-CD34 magnetic beads using two successive 
separations over LS MACS columns. For the functional evaluation CD34+ cells isolated from 
Buffy Coats were cultured in serum-free HPGM™ (Hematopoietic Progenitor Growth 
Medium; Lonza) supplemented with 50 ng/ml Flt-3L (Peprotech), 25ng/ml stem cell factor 
(SCF, Peprotech) and 50ng/ml TPO (Peprotech) as described previously with some minor 
modifications.(2) The amount of the CD34+ cells after the isolation from patients was 
between 105 and 1,5 X 105 and from Buffy Coats between 5 X 105 and 8 X 105. 
 
RNA Isolation, microRNA Array and Real-Time PCR Analysis 
Total RNA was isolated from CD34+ cells from patients with sCAD, STEMI events or healthy 
subjects using QIAzol Reagent (Qiagen) and miRNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions. Differential miR-expression in CD34+ cells was analysed using 
PCR-based miRNA profiling on Human panel I plates from Exiqon. Differential expression of 
individual miRs between the patient groups (STEMI at day 0 and day 5, sCAD and healthy 
subjects) was validated using Real-Time PCR analysis according to miRCURY LNA™ 
Universal RT microRNA PCR protocol (Exiqon). cDNA was synthesized from 5ng of total 
RNA with Universal cDNA Synthesis Kit (Exiqon), according to the manufacturer’s 
instruction. 
Real-Time PCR was performed using the SYBR Green master mix (Exiqon) and for each 
microRNA specific LNA PCR primer set (Exiqon) with a MX3000P PCR cycler. The qPCR 
data were normalized to the miR-103-values and relative miRNA expression was calculated 
using the 2-ΔΔCt method.  
 
Transfection of CD34+ progenitor cells with miR-mimic and anti-miR 
CD34+ progenitor cells isolated from Buffy Coats (leukocytes and thrombocytes from blood 
donations) were resuspended in antibiotic-free growth medium and transfected using 2µL 
Lipofectamine 2000 (Invitrogen) with 50-100nM miR-mimic (pre-miR) or anti-miR of miR-378, 
let-7b and miR-181a or with scramble-miR (prenegK2 for miR-mimic control and anti-control 
for anti-miR control, Ambion), using Lipofectamine 2000 (Invitrogen) according to 
manufacturer’s protocol. Four hours after incubation, transfection medium was removed and 
transfected CD34+ cells were seeded in 12-well suspension cell culture plates with fresh 
growth medium. Transfected CD34+ cells were used for the experiments after 48 hours.  
 
Transfection efficiency 
CD34+ progenitor cells were transfected in antibiotic-free growth medium using 2µL 
Lipofectamine 2000 (Invitrogen) with 100nM Cy3 labeled pre-miR positive control and anti-
miR negative control (Ambion) according to manufacturer’s protocol. 4 hours after 
transfection CD34+ cells were washed stained with DAPI (1:1000) for additional 2 hours. 
Afterwards, transfection efficacy was quantified by fluorescence imaging and FACS-
measurement for total Cy3 positive cells. 
 
Proliferation assay 
WST1-proliferation assay (Roche) was measured in CD34+ progenitor cells isolated from 
Buffy Coats according to manufacturer protocol. In detail, 1*104 transfected CD34+ cells were 
cultured for 24 hours in culture medium, containing 10% WST1 proliferation reagent. The 
proliferation measurement was performed by reading absorbance at 450nm. 
 
Matrigel angiogenesis assay in-vitro (tube formation) 
Human umbilical vein endothelial cells (HUVECs, Lonza) were cultured in endothelial cell 
growth medium (EGM-2: endothelial cell basal medium (EBM-2) with SingleQuots®, Lonza) 
with 10% FCS before being plated in 96-well plates (1x104 cells per well) previously coated 
with 25µl of Matrigel (growth factor-reduced; BD Biosciences). CD34+ cells (5x103 cells per 
well) from the study subjects or transfected CD34+ cells from Buffy Coats (5x103 cells per 
well) in 100µl of EBM-2 medium with 1% FCS were added for co-culture. After 18h of culture, 
tube-like structures were visualized and quantified per well using an inverted cell culture 
microscope and a digital camera (Nikon Ti-90) at 4x magnification as described in detail 
previously.(3)  
 
Scratch migration assay  
HUVECs (5x104 per well) were seeded into 12-well plates and cultured in EGM-2 Medium 
with 10% FCS until cells form 90%–100% confluent monolayers. The scratch was performed 
with sterile P10 pipette tips. HUVECs were washed with PBS to remove cellular debris and 
floating cells, and cultured with transfected CD34+ cells from Buffy Coats (4x104 cells per 
well) in 1 ml EBM-2 Medium containing 1% FCS. The cell migration capacity was measured 
as migration index I for quantification of total migration capacity, representing not only 
distance but total area for migration. This was described earlier by Menon et al.(4) Therefore, 
the scratched area was photographed under an inverted microscope (Nikon Ti-90) at the 
time points 0 and 8 hours. 
 
Cytokine assay 
ELISA-based Bioplex-Cytokine assay (Bio-Rad) was performed per manufacturer 
instructions. Therefore, 6*105 transfected CD34+ cells from Buffy Coats cells were cultured 
for 48 h and supernatant was collected, spinned down to avoid cell contamination and frozen 
until use. 
 
Co-culture assay 
Co-culturing of CD34+ cells and HUVECs was performed in 24-well-plates with trans-well 
inserts (BD Biosciences). HUVECs were prior seeded with 2,5*104 cells and grown until 
confluence. 7*104 CD34+ cells from Buffy Coats were transfected as described previously 
and washed twice with PBS before loading in 4µm trans-well inserts, which were already 
inserted in 24-well-plates. These CD34+ cells and HUVECs were co-cultured for 48 h in 
EGM2. Afterwards, supernatant and HUVECs were collected and subsequent Real-Time 
PCR was performed. 
 
In-vivo matrigel plug assay 
Animal experiments were approved by the local committee. Male NRMI nu/nu mice, aged 10-
16 weeks were used for transplantation of human MNC sub populations. Mice were housed 
under specific pathogen-reduced conditions receiving autoclaved chow and water ad libitum.  
In-vivo matrigel plug assay was performed as described previously(5) with the following 
modifications: CD34+ cell fraction from Buffy Coats transfected with anti-miR, miR-mimic or 
scramble miR (1x105) were re-suspended in 100 µL of Matrigel Basement Membrane Matrix 
(BD Biosciences) containing 15 U of heparin (Sigma-Aldrich) and injected subcutaneously 
into 10 to 12 week-old male athymic nude mice along the abdominal midline. After 5 days, 
blood vessel infiltration in Matrigel plugs was quantified by analysis of CD31-staining (BD 
pharmingen) with FITC-anti-rat antibody (AbD Serotec). Sections were photographed with an 
inverted microscope (Olympus) at 10x magnification. 
 
Chicken egg vascularization assay 
The in-vivo angiogenesis assay was performed as described in detail previously,(6) using an 
assay allowing analysis of angiogenic properties of low numbers of CD34+ progenitor cells. In 
brief, fertilized chicken eggs were incubated 3 days at 37°C before moving them in petri 
dishes (Corning Tissue Culture Dishes, Polystyrene, Sterile 100x20). After 7 further days of 
incubation, 100μl EGM-2 medium, scramble-miR or miR-mimic-378 transfected CD34+ cells 
from Buffy Coats were resuspended in 100μl EGM-2 medium and implanted using silicone 
rings with 15mm diameter. Pictures of the chorioallantoic membrane (CAM) and embryo 
were taken after 0 and 48 hours with Leica M205 FA and Canon EOS 5D. Differences of 
vessel length within the chorioallantoic membrane between these time points were 
determined. 
 
Statistical analysis 
Data are presented as mean±SEM. Shapiro-Wilk and Kolmogorov-Smirnov tests were used 
to test for non-Gaussian distribution. Differences between groups were analysed by student 
t-test for two groups or by one-way ANOVA and followed by Dunnett T3 or Bonferroni´s 
multiple comparison test as a post hoc tests for normal distribution values. For variables 
without normal distribution Mann-Whitney U test or Kruskal-Wallis were used. Fisher´s exact 
test was used for comparison of qualitative data. All tests were performed two sided and a p-
value of less than 0.05 was considered as statistically significant. Statistical analyses were 
performed using SPSS (version 21.0, SPSS Inc.) and GraphPad Prism 5. 
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Supplemental Figure I. FACS results after CD34+ cells isolation with anti-CD34 magnetic beads using two successive
separations over LS MACS columns.
Supplemental material
Supplemental Figure II. Heat Map of all microRNAs with a significant
difference between healthy subjects and STEMI d0 (p ≤ 0.05) in the miR-
Array of CD34+ progenitor cells. The highest fold change to healthy
subjects over 0 is labeled in green and below 0 in red.
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Supplemental Figure III. Results of the miRNA profiling and validation with Real-Time PCR. Micro-RNA expression levels for
the miRNAs: A, miR-199a-5p, B, miR-299 , C, miR-376b, D, miR-376c, E, miR-125a in CD34+ cells, isolated from study
subjects. *=p<0.05, **=p<0.01,data are mean ± SEM
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Supplemental Figure IV. Proliferation assay. Proliferation of CD34+ progenitor cells (1*104) transfected with A, pre-let-7b,
B, anti-let-7b, C, pre-181a and D, anti-miR-181a, quantified with WST1 proliferation reagent. *=p<0.05, data are mean ±
SEM
76% 80%
Supplemental Figure V. Transfection efficiency. A, FACS results 4h after
transfection of the CD34+ cells with Cy-3 labeled pre-miR and anti-miR negative
control. B, DAPI labeled CD34+ cells 4h after transfection with Cy-3 labeled pre-miR
and anti-miR negative control (red). C, Micro-RNA expression levels in CD34+ cells
after transfection with pre-miR or anti-miR.
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Supplemental Figure VI. In-vitro assays with scramble transfected CD34+ cells compared to pre-/anti-let-7b transfected CD34+
cells. A, Tube Formation angiogenesis assay with HUVECs (1x104) co-cultered for 18h with CD34+ transfected cells (5x103).
Tube-like structures were quantified. B, Endothelial scratch migration assay. After scratching, HUVECs were cultured in
starvation medium with scramble/miR-mimic-/anti-let-7b transfected CD34+ cells (4x104). The stimulatory effect of transfected
CD34+ cells on endothelial cell migration capacity was measured using the migration index (8 hours after scratch). *=p<0.05,
**=p<0.01,data aremean ± SEM
A
B
Supplemental Figure VII. Tube formation matrigel in-vitro assay with
HUVECs (green) and CD34+ cells (red).
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Supplemental Figure VIII. In-vitro assays with scramble transfected HUVECs compared to pre-/anti-miR-181a transfected
HUVECS.Tube Formation angiogenesis assaywith transfected HUVECs (1x104.Tube-like structureswere quantified.
PECAM-1
pre
ne
gK
2
pre
-m
iR-
37
8
an
ti-c
on
tro
l
an
ti-m
iR-
37
8
0.0
0.5
1.0
1.5
2.0
2.5 0.37
*
fo
ld
ch
an
ge
vs
.c
on
tr
ol
Follistatin
pre
ne
gK
2
pre
-m
iR-
37
8
an
ti-c
on
tro
l
an
ti-m
iR-
37
8
0.0
0.5
1.0
1.5
2.0
2.5
3.0
ns
ns
fo
ld
ch
an
ge
vs
.c
on
tr
ol
Leptin
pre
ne
gK
2
pre
-m
iR-
37
8
an
ti-c
on
tro
l
an
ti-m
iR-
37
8
0.0
0.5
1.0
1.5
2.0
ns
ns
fo
ld
ch
an
ge
vs
.c
on
tr
ol
VEGF
pre
ne
gK
2
pre
-m
iR-
37
8
an
ti-c
on
tro
l
an
ti-m
iR-
37
8
0.0
0.5
1.0
1.5
2.0
2.5
ns
ns
fo
ld
ch
an
ge
vs
.c
on
tr
ol
HGF
pre
ne
gK
2
pre
-m
iR-
37
8
an
ti-c
on
tro
l
an
ti-m
iR-
37
8
0.0
0.5
1.0
1.5
2.0
2.5
ns
ns
fo
ld
ch
an
ge
vs
.c
on
tr
ol
A B C
D E
Supplemental Figure IXa. Cytokine assay with supernatant from CD34+ scramble/pre-/anti-miR-378 transfected cells for the
following cytokines:A, FollistatinB, PECAM-1 C, LeptinD, VEGF E, HGF. Data aremean ± SEM
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Supplemental Figure IXb. Cytokine assay with supernatant from CD34+ scramble/pre-/anti-let-7b transfected cells for the
following cytokines:A, FollistatinB, PECAM-1 C, LeptinD, VEGF E, HGF. Data aremean ± SEM
Sc
r
an
ti-l
et 
7b
pre
-le
t 7
b
0
100
200
300
400
*
***
N
o.
 o
f C
D
31
 c
el
ls
/h
ig
h 
po
w
er
 fi
el
d
In-vivomatrigel plug assay
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Supplemental Figure X. In-vivo matrigel plug assay. Blood vessel infiltration in Matrigel plugs containing (1x105)
scramble/anti-/pre-miR-let-7b transfected CD34+ cells was quantified by analysis of CD31-staining 5 days after
injection. *=p<0.05, ***=p<0.001,data aremean ± SEM
Supplemental Table I. MiRNA-array for CD34+ cells derived from healthy subjects, sCAD, STEMI d0 and 
STEMI d5 patients. The geomean of all assays detected in all samples was used for normalizing the data. 
Normalized data are Cp mean ± SEM, ranked by p-value between healthy subjects and STEMI d0. Difference in 
normalized Cps (ΔΔCp) between healthy subjects and STEMI d0 has been calculated. A fold change > 1 
indicate up-regulation in STEMI d0 samples and a fold change < 1 indicate down-regulation in STEMI d0 
samples compared to healthy control samples.  Fold change = 2 ΔΔCp. Only miRNAs measureable in all patients 
are provided. 
Upregulated miRNAs in STEMI d0 samples compared to healthy subjects samples 
miR-name Healthy 
subjects 
SEM sCAD SEM STEMI 
d0 
SEM STEMI 
d5 
SEM p-value Fold 
change 
hsa-miR-1979 3,44 0,09 3,69 0,24 4,28 0,10 4,38 0,15 0,0008 1,79 
hsa-miR-199b-5p -3,53 0,14 -3,03 0,10 -2,68 0,08 -2,46 0,15 0,0018 1,81 
hsa-miR-125a-5p 1,00 0,06 1,29 0,16 1,59 0,10 1,54 0,10 0,0021 1,50 
hsa-miR-20b -0,24 0,14 0,09 0,23 0,55 0,10 0,39 0,20 0,0038 1,73 
hsa-miR-378 -1,65 0,16 -1,16 0,35 -0,71 0,13 -0,79 0,20 0,0040 1,91 
hsa-miR-93 2,64 0,05 2,75 0,14 3,02 0,07 2,88 0,07 0,0062 1,30 
hsa-miR-181a 2,98 0,28 3,09 0,40 4,20 0,16 3,85 0,18 0,0094 2,32 
hsa-miR-17 3,77 0,07 3,96 0,19 4,16 0,08 4,07 0,13 0,0095 1,32 
hsa-miR-424 0,04 0,19 0,38 0,38 1,05 0,19 0,64 0,27 0,0098 2,02 
hsa-miR-19b 5,23 0,08 5,46 0,28 5,80 0,13 5,66 0,14 0,0108 1,48 
hsa-miR-181b -1,92 0,38 -1,48 0,45 -0,31 0,23 -0,60 0,25 0,0116 3,05 
hsa-miR-106a 3,68 0,07 3,88 0,19 4,12 0,10 4,01 0,11 0,0116 1,35 
hsa-miR-155 0,05 0,33 0,55 0,34 1,36 0,15 1,05 0,16 0,0116 2,47 
hsa-let-7b 0,74 0,11 0,97 0,18 1,42 0,16 1,38 0,15 0,0130 1,61 
hsa-miR-181d -0,75 0,28 -0,78 0,42 0,57 0,26 0,15 0,23 0,0136 2,49 
hsa-miR-501-5p -7,11 0,37 -6,53 0,34 -5,25 0,40 -5,42 0,38 0,0137 3,64 
hsa-miR-21* -5,47 0,11 -4,90 0,38 -4,66 0,21 -5,15 0,37 0,0139 1,75 
hsa-miR-92a-1* -5,09 0,46 -4,62 0,61 -3,36 0,27 -4,09 0,43 0,0172 3,32 
hsa-miR-34a -3,73 0,21 -2,93 0,31 -2,55 0,31 -2,24 0,36 0,0195 2,26 
hsa-miR-18a* -3,62 0,19 -3,03 0,21 -2,62 0,26 -2,69 0,19 0,0201 2,01 
hsa-miR-92a 4,07 0,09 4,26 0,28 4,75 0,20 4,64 0,17 0,0219 1,60 
hsa-miR-20a 4,48 0,06 4,69 0,22 4,99 0,14 4,90 0,14 0,0242 1,43 
hsa-miR-99a* -5,50 0,29 -5,84 0,61 -4,52 0,18 -5,55 0,36 0,0277 1,97 
hsa-miR-106b 0,94 0,06 0,98 0,13 1,19 0,07 1,13 0,11 0,0311 1,19 
hsa-miR-582-5p -4,30 0,37 -4,44 0,51 -2,95 0,32 -3,11 0,40 0,0335 2,55 
hsa-miR-125b -0,27 0,34 0,15 0,57 1,11 0,37 0,68 0,27 0,0353 2,59 
hsa-miR-196b -0,23 0,26 -0,13 0,40 0,79 0,29 0,65 0,35 0,0370 2,03 
hsa-miR-500 -5,58 0,39 -5,03 0,37 -4,21 0,35 -4,36 0,28 0,0385 2,60 
hsa-miR-197 -0,23 0,09 -0,08 0,17 0,18 0,13 0,12 0,14 0,0414 1,33 
hsa-miR-140-5p -1,35 0,10 -1,29 0,13 -0,98 0,11 -1,05 0,17 0,0437 1,30 
hsa-miR-10b -3,01 0,41 -2,84 0,33 -1,82 0,24 -1,69 0,39 0,0450 2,28 
hsa-miR-25 -0,15 0,06 -0,06 0,20 0,27 0,14 0,32 0,11 0,0510 1,34 
hsa-miR-181c -2,93 0,19 -2,84 0,42 -2,20 0,25 -2,18 0,29 0,0547 1,66 
hsa-miR-181a* -4,06 0,50 -3,62 0,39 -2,57 0,38 -3,20 0,21 0,0552 2,80 
hsa-miR-222 1,61 0,22 1,87 0,39 2,33 0,21 2,10 0,22 0,0570 1,65 
hsa-let-7g 3,16 0,08 3,25 0,12 3,37 0,04 3,17 0,04 0,0581 1,16 
hsa-miR-19a 4,53 0,05 4,66 0,19 4,90 0,15 4,80 0,14 0,0588 1,29 
hsa-miR-365 -4,60 0,40 -4,44 0,50 -3,53 0,23 -3,41 0,24 0,0599 2,10 
hsa-miR-99a -0,93 0,35 -0,55 0,56 0,23 0,36 -0,05 0,27 0,0607 2,23 
hsa-miR-720 2,74 0,13 3,19 0,29 3,54 0,29 3,77 0,22 0,0608 1,75 
hsa-miR-363 -2,64 0,16 -2,33 0,34 -1,98 0,25 -1,85 0,18 0,0655 1,59 
hsa-miR-629 -5,60 0,50 -4,81 0,25 -4,31 0,33 -4,26 0,26 0,0769 2,44 
hsa-miR-324-3p -1,50 0,14 -1,23 0,12 -1,15 0,10 -1,35 0,10 0,0827 1,27 
hsa-miR-92b -4,90 0,27 -4,32 0,27 -3,97 0,39 -4,12 0,35 0,0962 1,90 
hsa-miR-196a -5,69 0,51 -6,21 0,46 -4,52 0,22 -4,97 0,20 0,1015 2,26 
hsa-miR-10a -0,70 0,37 -0,45 0,54 0,34 0,43 0,29 0,36 0,1143 2,06 
hsa-miR-532-5p -4,03 0,25 -3,94 0,26 -3,48 0,17 -3,55 0,25 0,1186 1,46 
hsa-miR-146b-5p -2,36 0,32 -1,92 0,14 -1,48 0,37 -1,45 0,17 0,1201 1,85 
hsa-miR-651 -6,61 0,37 -6,76 0,13 -5,91 0,20 -6,29 0,20 0,1491 1,62 
hsa-miR-15a 4,00 0,10 4,20 0,12 4,25 0,12 4,12 0,12 0,1655 1,19 
hsa-miR-421 -4,44 0,19 -4,18 0,20 -4,09 0,16 -4,15 0,15 0,2025 1,27 
hsa-miR-140-3p 0,25 0,11 0,20 0,14 0,45 0,12 0,48 0,12 0,2566 1,16 
hsa-miR-660 -5,02 0,11 -5,14 0,46 -4,83 0,11 -4,61 0,37 0,2697 1,14 
hsa-miR-192 -3,65 0,08 -3,78 0,16 -3,26 0,32 -3,33 0,17 0,3168 1,31 
hsa-miR-450a -4,52 0,27 -4,55 0,30 -4,01 0,42 -4,20 0,41 0,3422 1,43 
hsa-let-7c 1,30 0,04 1,23 0,13 1,44 0,12 1,60 0,08 0,3514 1,10 
hsa-miR-32 -4,98 0,29 -4,65 0,38 -4,60 0,25 -5,25 0,12 0,3566 1,30 
hsa-miR-7 -6,82 0,48 -6,12 0,39 -6,30 0,22 -6,08 0,19 0,3766 1,44 
hsa-miR-16 4,39 0,19 4,61 0,17 4,59 0,09 4,58 0,13 0,3846 1,15 
hsa-miR-29b-2* -4,39 0,13 -4,48 0,24 -4,02 0,36 -4,88 0,13 0,3896 1,29 
hsa-miR-338-3p -0,36 0,12 -0,20 0,10 -0,17 0,18 -0,28 0,18 0,4235 1,14 
hsa-miR-200a -7,40 0,17 -6,80 0,54 -6,99 0,46 -6,31 0,49 0,4289 1,33 
hsa-miR-423-3p 1,86 0,16 1,97 0,10 2,00 0,05 1,91 0,04 0,4369 1,10 
hsa-miR-361-3p -2,47 0,18 -2,37 0,16 -2,24 0,23 -2,44 0,25 0,4653 1,17 
hsa-miR-194 -5,48 0,11 -5,42 0,13 -5,36 0,16 -5,27 0,07 0,5381 1,09 
hsa-miR-30e* -1,46 0,06 -1,60 0,11 -1,42 0,04 -1,47 0,09 0,5902 1,03 
hsa-miR-423-5p -0,88 0,07 -0,88 0,05 -0,82 0,09 -0,97 0,09 0,6030 1,04 
hsa-miR-296-5p -4,55 0,38 -4,71 0,35 -4,23 0,50 -4,37 0,34 0,6294 1,25 
hsa-miR-215 -5,53 0,14 -5,52 0,08 -5,40 0,22 -5,66 0,14 0,6334 1,10 
hsa-miR-320a 2,01 0,14 2,20 0,10 2,12 0,19 2,16 0,09 0,6373 1,08 
hsa-miR-505 -2,90 0,18 -2,74 0,05 -2,81 0,06 -2,57 0,09 0,6472 1,07 
hsa-miR-342-3p 1,00 0,23 0,88 0,25 1,15 0,21 1,00 0,07 0,6502 1,11 
hsa-miR-301b -4,02 0,28 -4,27 0,21 -3,86 0,25 -4,19 0,16 0,6964 1,11 
hsa-miR-30b 3,78 0,10 3,73 0,13 3,81 0,06 3,72 0,03 0,8064 1,02 
hsa-miR-186 0,22 0,03 0,21 0,08 0,24 0,11 0,26 0,08 0,8084 1,02 
hsa-miR-30e 2,03 0,08 1,83 0,13 2,06 0,10 1,90 0,10 0,8242 1,02 
hsa-miR-135a -7,16 0,34 -7,26 0,16 -7,08 0,21 -6,68 0,30 0,8427 1,06 
hsa-let-7d* -0,67 0,15 -0,55 0,09 -0,67 0,06 -0,55 0,05 0,9743 1,00 
hsa-miR-195 -3,66 0,41 -3,90 0,31 -3,64 0,18 -3,78 0,12 0,9797 1,01 
hsa-let-7f 3,40 0,07 3,26 0,08 3,40 0,04 3,29 0,01 0,9853 1,00 
hsa-let-7a 3,89 0,18 3,78 0,20 3,89 0,61 4,07 0,13 0,9950 1,00 
hsa-miR-142-3p 6,82 0,11 6,79 0,14 6,83 0,07 6,78 0,10 0,9963 1,00 
 
Downregulated miRNAs in STEMI d0 samples compared to healthy subjects samples 
miR-name Healthy 
subjects 
SEM sCAD SEM STEMI 
d0 
SEM STEMI 
d5 
SEM p-value Fold 
change 
hsa-miR-299-5p -4,55 0,26 -4,60 0,70 -6,46 0,17 -6,00 0,45 ,001 0,27 
hsa-let-7i 1,02 0,05 0,88 0,08 0,58 0,03 0,69 0,13 ,001 0,74 
hsa-miR-374b 0,11 0,08 -0,02 0,15 -0,40 0,03 -0,14 0,03 ,001 0,71 
hsa-miR-487b -5,24 0,33 -6,24 1,00 -7,34 0,22 -6,98 0,46 ,002 0,23 
hsa-miR-199a-5p 1,80 0,10 1,41 0,24 0,42 0,25 0,43 0,28 ,002 0,38 
hsa-miR-151-5p 2,10 0,09 1,59 0,27 0,87 0,23 0,99 0,22 ,002 0,43 
hsa-miR-199a-3p 0,68 0,19 0,30 0,28 -0,72 0,23 -0,47 0,28 ,003 0,38 
hsa-miR-152 -1,68 0,24 -2,01 0,20 -2,83 0,03 -2,64 0,20 ,003 0,45 
hsa-miR-486-5p -0,91 0,04 -1,12 0,39 -1,94 0,16 -1,79 0,34 ,006 0,49 
hsa-miR-376c -1,50 0,39 -2,34 0,89 -3,54 0,38 -3,30 0,56 ,010 0,24 
hsa-miR-376b -2,84 0,33 -3,87 1,01 -5,24 0,57 -5,09 0,57 ,011 0,19 
hsa-miR-326 -0,67 0,11 -0,97 0,17 -1,60 0,24 -1,57 0,13 ,013 0,53 
hsa-miR-185 1,78 0,05 1,70 0,21 1,10 0,14 1,30 0,15 ,013 0,63 
hsa-miR-376a -1,11 0,43 -2,14 1,02 -3,18 0,44 -2,87 0,56 ,015 0,24 
hsa-miR-411 -3,64 0,33 -4,39 0,94 -5,62 0,49 -5,68 0,77 ,016 0,25 
hsa-miR-22 -1,13 0,22 -1,30 0,21 -2,31 0,28 -1,97 0,25 ,017 0,44 
hsa-miR-154 -2,58 0,46 -3,51 0,79 -4,76 0,49 -4,29 0,64 ,018 0,22 
hsa-miR-23b 4,21 0,10 4,12 0,11 3,84 0,06 3,80 0,06 ,020 0,77 
hsa-miR-221 2,80 0,09 2,73 0,15 2,38 0,10 2,34 0,14 ,022 0,75 
hsa-let-7d -0,06 0,09 -0,19 0,08 -0,41 0,07 -0,18 0,08 ,022 0,79 
hsa-miR-142-5p 1,93 0,08 1,88 0,05 1,49 0,12 1,53 0,10 ,023 0,74 
hsa-miR-127-3p -2,55 0,16 -2,88 0,89 -4,10 0,50 -3,72 0,58 ,025 0,34 
hsa-miR-382 -2,78 0,42 -3,58 0,75 -4,69 0,49 -4,62 0,67 ,025 0,27 
hsa-miR-153 -4,93 0,17 -5,50 0,65 -5,91 0,29 -5,91 0,24 ,027 0,51 
hsa-miR-23a 4,61 0,12 4,47 0,06 4,09 0,14 4,22 0,08 ,027 0,69 
hsa-miR-200c -3,91 0,13 -3,98 0,21 -4,45 0,14 -3,97 0,25 ,033 0,69 
hsa-miR-652 0,00 0,16 -0,25 0,14 -0,53 0,05 -0,52 0,16 ,035 0,69 
hsa-miR-584 -3,39 0,32 -3,85 0,46 -4,46 0,30 -4,25 0,44 ,050 0,48 
hsa-miR-133a -2,08 0,26 -2,09 0,56 -3,01 0,28 -2,55 0,49 ,052 0,52 
hsa-miR-191 1,74 0,07 1,61 0,12 1,43 0,11 1,54 0,12 ,054 0,80 
hsa-miR-24 4,01 0,06 4,05 0,05 3,84 0,04 3,89 0,07 ,061 0,89 
hsa-miR-28-5p -0,51 0,12 -0,53 0,12 -1,00 0,18 -0,86 0,05 ,061 0,71 
hsa-miR-103 4,73 0,15 4,59 0,07 4,35 0,08 4,33 0,09 ,066 0,77 
hsa-miR-328 -1,21 0,05 -1,33 0,16 -1,36 0,05 -1,48 0,07 ,071 0,90 
hsa-miR-330-3p -4,74 0,27 -5,18 0,21 -5,40 0,13 -4,98 0,18 ,075 0,64 
hsa-miR-148b 0,92 0,14 0,70 0,04 0,37 0,21 0,31 0,16 ,083 0,69 
hsa-miR-145 -0,65 0,14 -0,59 0,49 -1,40 0,36 -1,37 0,35 ,101 0,59 
hsa-miR-21 4,48 0,11 4,53 0,29 4,01 0,23 4,40 0,46 ,108 0,72 
hsa-miR-148a -1,70 0,36 -1,64 0,17 -2,58 0,31 -2,23 0,29 ,111 0,54 
hsa-miR-744 -3,84 0,26 -4,14 0,18 -4,42 0,06 -4,40 0,15 ,112 0,67 
hsa-miR-625* -3,80 0,37 -4,22 0,49 -4,85 0,43 -4,50 0,29 ,114 0,48 
hsa-miR-126 4,84 0,12 4,82 0,21 4,59 0,06 4,61 0,11 ,114 0,84 
 hsa-miR-22* -2,24 0,17 -2,09 0,19 -2,98 0,37 -2,78 0,29 ,117 0,60 
hsa-miR-107 3,37 0,08 3,15 0,16 2,92 0,21 3,12 0,09 ,121 0,73 
hsa-miR-182 -5,23 0,39 -5,75 0,46 -6,39 0,52 -6,07 0,45 ,124 0,45 
hsa-miR-29c 0,80 0,16 0,61 0,18 0,42 0,16 0,57 0,09 ,137 0,76 
hsa-miR-484 1,63 0,14 1,58 0,14 1,28 0,15 1,34 0,12 ,149 0,79 
hsa-miR-18a -0,84 0,10 -0,94 0,19 -1,09 0,12 -1,11 0,13 ,156 0,84 
hsa-miR-1 -3,14 0,35 -2,91 0,53 -4,26 0,60 -4,07 0,54 ,158 0,46 
hsa-miR-425 0,73 0,10 0,70 0,06 0,54 0,07 0,60 0,07 ,164 0,88 
hsa-miR-26b 1,47 0,12 1,38 0,21 1,26 0,05 1,27 0,16 ,173 0,87 
hsa-miR-143 -1,35 0,22 -1,57 0,44 -2,00 0,38 -2,05 0,33 ,193 0,64 
hsa-miR-628-3p -4,36 0,20 -5,04 0,14 -5,08 0,43 -5,16 0,08 ,196 0,61 
hsa-miR-133b -3,58 0,26 -3,39 0,42 -4,34 0,48 -3,95 0,48 ,213 0,59 
hsa-miR-139-5p -1,33 0,16 -0,97 0,54 -1,68 0,21 -1,78 0,48 ,217 0,78 
hsa-miR-340 -3,73 0,30 -3,99 0,18 -4,86 0,88 -4,72 0,42 ,273 0,46 
hsa-miR-331-3p -0,23 0,17 -0,26 0,15 -0,45 0,08 -0,60 0,09 ,275 0,86 
hsa-miR-339-5p -0,73 0,14 -1,09 0,08 -0,95 0,12 -0,87 0,09 ,292 0,86 
hsa-miR-29b -1,06 0,23 -1,13 0,16 -1,38 0,16 -1,75 0,53 ,298 0,80 
hsa-miR-301a -1,31 0,24 -1,67 0,30 -1,76 0,32 -1,66 0,33 ,306 0,73 
hsa-miR-30d 1,06 0,20 0,63 0,13 0,79 0,13 0,87 0,19 ,311 0,83 
hsa-miR-590-5p -0,62 0,14 -0,62 0,15 -0,79 0,07 -1,00 0,19 ,314 0,89 
hsa-miR-193b -6,06 0,30 -6,71 0,27 -6,90 0,73 -5,35 0,27 ,333 0,56 
hsa-miR-30a -1,47 0,29 -1,54 0,36 -1,93 0,35 -1,44 0,17 ,352 0,73 
hsa-miR-497 -4,39 0,33 -4,47 0,14 -4,89 0,38 -4,47 0,13 ,359 0,71 
hsa-miR-425* -1,98 0,12 -2,19 0,14 -2,14 0,12 -2,29 0,12 ,380 0,89 
hsa-miR-150 2,75 0,32 2,14 0,27 2,34 0,33 2,46 0,19 ,407 0,75 
hsa-miR-141 -4,78 0,06 -4,73 0,22 -5,24 0,49 -5,10 0,26 ,418 0,73 
hsa-miR-130b -3,97 0,12 -4,13 0,18 -4,09 0,12 -4,13 0,14 ,514 0,92 
hsa-miR-766 -1,06 0,06 -1,09 0,14 -1,15 0,13 -1,17 0,13 ,521 0,94 
hsa-miR-9 -6,15 0,19 -5,47 0,43 -6,63 0,66 -6,41 0,20 ,531 0,72 
hsa-miR-146a -0,14 0,12 -0,12 0,20 -0,38 0,35 -0,46 0,15 ,565 0,85 
hsa-miR-130a 0,03 0,13 0,11 0,16 -0,07 0,14 -0,09 0,12 ,600 0,93 
hsa-miR-99b -1,02 0,07 -1,12 0,22 -1,14 0,21 -1,38 0,26 ,621 0,92 
hsa-miR-98 -4,74 0,19 -4,61 0,10 -4,84 0,10 -4,97 0,18 ,636 0,93 
hsa-miR-503 -3,70 0,36 -3,52 0,49 -3,90 0,26 -3,75 0,25 ,673 0,87 
hsa-miR-29a 0,07 0,15 0,06 0,18 0,00 0,10 0,09 0,06 ,694 0,95 
hsa-miR-223 7,01 0,09 6,99 0,04 6,95 0,17 6,87 0,14 ,751 0,96 
hsa-miR-451 0,30 0,23 0,04 0,36 0,15 0,43 0,63 0,45 ,771 0,90 
hsa-let-7e -1,38 0,22 -1,33 0,14 -1,43 0,14 -1,28 0,22 ,841 0,96 
hsa-miR-18b 0,03 0,14 0,14 0,13 0,01 0,08 -0,13 0,21 ,899 0,99 
hsa-miR-335 -0,96 0,10 -1,17 0,32 -0,99 0,27 -1,27 0,07 ,919 0,98 
hsa-miR-15b 3,20 0,09 3,20 0,07 3,19 0,04 3,12 0,04 ,921 0,99 
